Immunodeficiency is an important feature in families with GATA2 mutations, with its specific susceptibility for infections with intracellular organisms such as atypical mycobacteria and viruses, which is also prominently featured in our family. Adequate GATA2 expression is crucial for myeloid differentiation of hematopoietic stem cells and deficiency leads to profound monocytopenia, necessary for the eradication of intracellular organisms. In most reported patients with DCML and MonoMac, the monocytopenia is accompanied by relative absence of NK-and B-cells while T-cell compartment is functionally and quantitatively unaffected. These findings were also reflected in our index patient where there was NK-and B-cell lymphopenia, without hypogammaglobulinaemia, while T-cell numbers and subsets were present and functional on stimulation with recall antigens.
Another disease entity, also featured in our family in patient II-8, is the occurrence of primary lymphedema, which has independently been reported by two different groups. 4, 6 In a recent article, Kazenwadel et al. 6 demonstrated that wild-type homozygous GATA2 is crucial for lymphoendothelial valve development and that knockdown of GATA2 in lymphatic endothelial valves leads to absent expression of genes important for valve development, thus explaining the mechanism of lymphedema.
The clinical heterogeneity of our pedigree illustrates that the interplay of additional molecular defects is likely to give rise to this striking variation in phenotype. We report for the first time, two novel mutations occurring in all affected cases in this family and also the first description of an aggressive T-cell NHL associated with GATA2 mutations.
GATA2 mutations have only been described recently and pedigrees are rare. For now, clinical management and guidelines for risk stratification and treatment are mostly based on expert opinion. 7 Since the discovery of the genetic defect, many new mutations in GATA2 have been reported but little is known yet about the precise functional effect of each different mutation. No clear relationship between genotype and phenotypical outcome has been described making prediction of clinical course, as well as identifying those who might benefit from early intervention such as allogeneic bone marrow transplantation, very challenging at the least.
The description of this pedigree, clearly illustrates that, even in the case of seemingly sporadic AML, which is most often not a familial disease entity, a thorough family history that goes beyond first-degree relatives and the exclusion of hematological malignancies, is clearly of importance in diagnosing a GATA2 mutation. Furthermore, in patients with a combination of unexplained immune deficiency, monocytopenia, lymphopenia, lymphedema and/or pulmonary defects, GATA2 mutation analysis should be considered. Although uncertainty in predicting clinical outcome of carriers could lead to reluctance in genetic testing, the identification of a germline GATA2 mutation should prevent unnecessary diagnostic procedures or intervention and could ensure regular follow-up with an appropriate management plan should symptoms or signs of disease develop. Also, given the possibility of asymptomatic carriage of first-degree family members, screening for GATA2 mutation should be considered when analyzing siblings as bone marrow donors. It will be a challenge elucidating the molecular effects of GATA2 mutation but a better understanding of phenotypical development is needed to identify those who are at high risk for developing MDS/AML and with this those who would benefit from early intervention. Follow-up of our large cohort might help delineate the phenotypical heterogeneity as all phenotypes are represented in one family affected with two germline mutation.
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The authors declare no conflict of interest. Letters to the Editor it is quite heterogeneous in terms of prognosis. Indeed, in these patients, the mutation status of different genes, in particular FLT3 (Fms-related Tyrosine Kinase 3) and NPM (Nucleophosmin), has important prognostic implications on the treatment outcome. 2, 3 Patients with mutated NPM (NPMc þ ) have a favourable outcome, 4 while patients with mutations in the FLT3 gene (FLT3-ITD) generally have a poor prognosis. 5 Interestingly, these two mutations are frequently associated in CN-AML patients, strongly suggesting that they cooperate to some extent in leukaemia development. 3 Patients with both mutations have a poor prognosis with respect to those only bearing the NPMc þ mutation and a better prognosis compared to those with the FLT3-ITD mutation alone. 6 These observations indicate complex interactions among different mutations, pointing out their important prognostic value. Model systems of AMLs with either one or both mutations are needed to investigate their relative contribution to leukaemogenesis.
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Here we report the results of our study on a new mouse model of NPMc þ -dependent leukaemia, showing the effect of the combination of NPMc þ and FLT3-ITD mutations on leukaemia development in this model.
We generated a transgenic NPMc þ mouse model by inserting the cDNA of the most frequent mutation of NPM (mutA-in about 80% of patients 4 ) into the Hprt locus, under the control of a strong and ubiquitous pCAG promoter (genOway, Lyon, France). The targeting vector was designed to contain a stop cassette flanked by loxP sites between the promoter and the cDNA, thus allowing the conditional expression of the NPM mutant protein upon Cre-mediated recombination. In order to obtain the haematopoietic specific expression of the mutant, bone marrow mononucleated cells (BM-MNCs) from NPMc þ and control mice were treated ex vivo with a recombinant Cre protein fused with the HIV-derived TAT protein (TAT-Cre), a polypeptide that confers to Cre the ability to penetrate into the cells and to target the floxed sequences. We have checked the expression of NPM mutant protein by western immunoblotting (WB) with an anti-NPMc þ monoclonal antibody that recognizes specifically only the mutant NPM 7 (Figure 1a ) and the percentage of recombination by immunofluorescence with the same antibody (average 38.9±5.15% in all experiments), confirming the typical cytoplasmic localization of the mutant NPM protein (Figure 1b) . The cytoplasmic localization has been also confirmed using an antibody that recognizes both endogenous and mutant NPM (Supplementary Figure 1) . C57BL/6 CD45.2 BMMNCs (either NPMc þ or wild type, WT) were treated with TAT-Cre and transplanted into C57BL/6 CD45.1-irradiated (6.5 Gy) recipient mice. The extent of the engraftment was assessed after 4 weeks (in NPMc þ mice 84.45±3.8% and in control mice 85.02±4.67%). Mice health was monitored weekly and animals were killed at the first sign of pain. Organs and cells were collected for further analyses, as described below. NPMc þ mice developed leukaemia at low penetrance (33.3% of animals developed the disease) and with a long latency (between 536 and 637 days; median survival of 564 days; Figure 1c ). Leukaemic mice displayed splenomegaly, leukocytosis, anaemia and thrombocytopenia (Supplementary Figure 2) . Bone marrow samples showed an overall increase in cellularity, with myeloid hyperplasia and signs of dysplasia of both the erythroid and megakaryocytic series. The myeloid compartment was left-shifted, with an increase in immature cells and an overall prevalence of myeloblasts (Figure 1d) . In extramedullary sites, including the spleen, liver, kidneys and lungs, we observed neoplastic aggregates composed of large cells with abundant cytoplasm and indented nuclei, suggesting monocyte differentiation (see Figure 1d for representative data). Blood smears were characterized by the occurrence of a high number of blasts (Figure 1d) . Fluorescence-activated cell sorting (FACS) analysis of bone marrow samples showed typical features of AMLs with maturation (Mac1 þ /Gr1 þ ), and in one case we observed a biphenotypic AML with both myeloid (Mac1 þ /Gr1 þ ) and B/ lymphoid (B220 þ ) lineage markers (data not shown). WB analysis of the spleen of these mice confirmed the expression of the NPM mutant protein in the leukaemic blasts (Supplementary Figure 3) .
These data are consistent with an NPMc þ knock-in mouse model recently reported by Vassiliou et al., 8 where the mutated NPM is expressed under the control of the NPM endogenous promoter. Also, in this case mice developed leukaemia late in life (about 30% of the animals) and about 50% of the leukaemia were bi-phenotypic (B/myeloid). Long latency and low penetrance suggest that NPMc þ needs additional mutations to support a full leukaemia phenotype, and that not all the animals acquire such mutations during their life span. Indeed, in the same paper, Vassiliou et al. also investigated the occurrence of cooperative mutations through transposon insertional mutagenesis. Among others, mutations in the Flt3 gene have been selected; however, under their experimental conditions, they isolate Flt3 mutations both in NPMc þ and WT mice, thus leaving open the question if FLT3 and NPM mutations significantly cooperate in leukaemia development. To address this question we have crossed our NPMc þ model with a knock-in FLT3-ITD mouse model. 9 FLT3-ITD animals have been shown to develop a myeloproliferative disease that did not progress to leukaemia. 9 NPMc þ /FLT3-ITD mice, instead, developed leukaemia very rapidly. Strikingly, all the NPMc þ /FTL3-ITD mice died of leukaemia between 35 and 161 days with a median survival of 72 days (Figure 2a) . Mice showed splenomegaly, leukocytosis, anaemia and thrombocytopenia (Supplementary Figure 2) . Bone marrow samples were characterized by a complete replacement of the haematopoietic series with a monotonous proliferation of blasts (Figure 2b ). In most of the cases, large neoplastic nodules composed of blasts with similar morphology were detected in extramedullary sites including the spleen, liver, kidneys, lungs, gut and heart (see Figure 2b ). Blood smears were characterized by the occurrence of a high number of blasts (Figure 2b ). FACS analysis of bone marrow samples showed 10 out of 16 AMLs analysed with maturation (Mac1 þ /Gr1 þ ) and the remaining 6 with bi-phenotypic markers (5 cases with both myeloid (Mac1 þ /Gr1 þ ) and B/lymphoid (B220 þ ) lineage markers; 1 case with both myeloid (Mac1 þ /Gr1 þ ) and T/lymphoid (CD3 þ ) lineage markers; not shown). WB analysis of five NPMc þ /FLT3-ITD AMLs showed the expression of NPMc þ in all samples (supplementary Figure 3) . The expression of NPMc þ has been correlated to overexpression of HOX genes both in human NPMc þ AMLs and in NPMc þ expressing mouse Lin À cells 8 . 10 This correlation was confirmed also in our NPMc þ and NPMc þ /FLT3-ITD mouse models (Supplementary Figure 4 and Supplementary Table 1 ).
Our data demonstrate that NPMc þ and FLT3-ITD mutations cooperate efficiently in inducing AMLs in mice. It has been proposed that AML is the consequence of the cooperation of two classes of mutations: class I mutations, conferring a proliferative and/or survival advantage, and class II mutations, which impair haematopoietic differentiation and/or self-renewal properties of the stem cells/progenitors. Consistently, FLT3-ITD is considered a class I mutation, while NPMc þ has been proposed to belong to class II, although there are no clear data yet. This model is strongly supported by our results. Moreover, the kinetic of leukaemia development in NPMc þ /FLT3-ITD animals compared to that of mice bearing only one of the two mutations would suggest that NPMc þ and FLT3-ITD mutations, when combined, are enough to initiate and promote leukaemogenesis. Alternatively, FLT3-ITD mutation provides proliferation and survival signalling that increase the occurrence of cooperative mutations. The wholegenome sequencing of NPMc þ versus NPMc þ /FLT3-ITD leukaemia should help in verifying these alternative hypotheses. Regardless, the NPMc þ and NPMc þ /FLT3-ITD mice represent ideal models of human AMLs to study the mechanism of leukaemogenesis and test innovative therapeutic approaches.
